CLAIMS AMENDMENT

Please cancel claims numbers 1-48.

Claims:

1-48. (canceled)

49. (currently amended): A method for expressing a ~~foreign gene~~ non-polio nucleotide sequence in a cell comprising:

contacting the cell, in a physiologically acceptable carrier, with an ~~effective~~ amount of a composition effective to result in said expression comprising a recombinant poliovirus nucleic acid having a ~~foreign~~ nucleotide sequence encoding, in an expressible form, a gene product substituted for at least a portion of the P1 capsid precursor region of the poliovirus genome,

under conditions appropriate for introduction of the recombinant poliovirus nucleic acid into the cell, thereby generating a modified cell which expresses a ~~foreign~~ said gene product encoded by ~~the foreign~~ said nucleotide sequence.

50. (previously presented): The method of claim 49 wherein the recombinant poliovirus nucleic acid is encapsidated.

51. (previously presented): The method of claim 49 wherein the cell is in a subject.

52. (previously presented): The method of claim 51 wherein the cell is contacted ex vivo and the modified cell is then reintroduced into the subject.

53. (previously presented): The method of claim 49 wherein the cell is selected from the group consisting of a peripheral blood mononuclear cell, a B cell, a T cell, a monocyte, a macrophage, a cutaneous cell, a muscle cell, a kidney cell, a mucosal cell, and a tumor cell.

54. (previously presented): The method of claim 52 wherein the cell is reintroduced into the subject by injection or implantation.

CLAIM AMENDMENTS

1-48. (canceled)

49. (currently amended): A method for expressing a ~~non-polio~~ nucleotide sequence encoding a therapeutic gene product in a cell comprising:

contacting a cell with an amount of a composition effective to result in expression of ~~a non-polio~~ said nucleotide sequence, said composition comprising a recombinant poliovirus nucleic acid having ~~a non-polio~~ said nucleotide sequence encoding, in an expressible form, a therapeutic gene product substituted for at least a portion of the P1 capsid precursor region of the poliovirus genome,

under conditions appropriate for introduction of the recombinant poliovirus nucleic acid into the cell, thereby generating a modified cell which expresses said gene product ~~encoded by said non-polio nucleotide sequence~~ , and

wherein the recombinant poliovirus nucleic acid is encapsidated; and said composition is substantially free of unmodified poliovirus.

nucleic acid

50. (canceled)

51. (previously presented): The method of claim 49 wherein the cell is in a subject.

52. (currently amended): The method of claim 51 wherein the cell is contacted ~~ex vivo~~ *ex vivo* and the modified cell is then reintroduced into the subject.

53. (previously presented): The method of claim 49 wherein the cell is selected from the group consisting of a peripheral blood mononuclear cell, a B cell, a T cell, a monocyte, a macrophage, a cutaneous cell, a muscle cell, a kidney cell, a mucosal cell, and a tumor cell.

54. (previously presented): The method of claim 52 wherein the cell is reintroduced into the subject by injection or implantation.

55. (currently amended): The method of claim 49 wherein ~~the non-polio~~ said nucleotide sequence encodes a gene product selected from the group consisting of a protein or fragment thereof, an antisense nucleotide sequence, and a ribozyme.

56. (currently amended): The method of claim 55 wherein the ~~protein~~ product is a therapeutic protein.

57. (previously presented): The method of claim 55 wherein the protein or fragment thereof is selected from the group consisting of a secretory protein, a cell surface protein, and a structural protein.

58. (previously presented): The method of claim 56 wherein the secretory protein is selected from the group consisting of an interleukin and a cytokine

59. (previously presented): The method of claim 58 wherein the interleukin is selected from the group consisting of IL-1, IL-2, and IL-6.

60. (previously presented): The method of claim 58 wherein the cytokine is selected from the group consisting of GM-CSF, and interferon-γ.

61. (previously presented): The method of claim 55 wherein the antisense nucleotide sequence corresponds to a gene selected from the group consisting of a viral gene and an oncogene.

62. (previously presented): The method of claim 61 wherein the viral gene is an HIV gene.

63. (previously presented): The method of claim 55 wherein the ribozyme comprises an activity selected from the group consisting of endonuclease activity and polymerase activity.